Antibody-drug conjugate targeting c-met and medical use thereof

Abstract

The invention relates to a c-Met targeting antibody-drug conjugate and a medical application thereof. The invention discloses an anti-c-Met antibody-drug conjugate with a structure as shown in formula (I): Ab-(L-Y-D) n (I), Ab is an anti-c-Met antibody, and L, Y and D are defined in the specification.

Description

(19) State Intellectual Property Office (12) Invention Patent Application (10) Application Publication Number (43) Application Publication Date (21) Application Number 202480043257.7 (22) Application Date 2024.07.25 (66) Domestic Priority Data 202310916920.7 2023.07.25 CN (85) PCT International Application Entering National Phase Date 2025.12.26 (86) PCT International Application Application Data PCT / CN2024 / 107536 2024.07.25 (87) PCT International Application Publication Data WO2025 / 021151 ZH 2025.01.30 (71) Applicant Jiangsu Hengrui Medicine Co., Ltd. Address 222047 No. 7 Kunlunshan Road, Economic and Technological Development Zone, Lianyungang City, Jiangsu Province Applicant: Shanghai Shengdi Pharmaceutical Co., Ltd. (72) Inventors: Tian Yunan, Sun Xing, Su Lu, Yuan Jimin, Liao Cheng (74) Patent Agency: Beijing Gecheng Intellectual Property Agency Co., Ltd. 11314 Patent Attorney: Cheng Wei (51) Int.Cl. A61K 47 / 68 (2006.01) A61K 31 / 506 (2006.01) A61P 35 / 00 (2006.01) (54) Invention Title: Antibody-Drug Conjugate Targeting c-Met and Its Pharmaceutical Use (57) Abstract: Antibody-Drug Conjugate Targeting c-Met and Its Pharmaceutical Use. The structure shown in formula (I): Ab-(L-Y-D)n(I) is an anti-c-Met antibody-drug conjugate, wherein Ab is an anti-c-Met antibody, and L, Y and D are as defined in the specification. CN 121487754 A 2026.02.06 CN 1 21 48 77 54 A

Images